MAPT and Alzheimer disease: Until now the tau fibril structuresfrom the patients of AD, CTE, and PiD are only available, and so weconsidered these targets.10,11,13 We carried out blind molecular docking to find out various possiblebinding sites for AV-1451 in three different tau fibrils.